Compare EMBC & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EMBC | ACIU |
|---|---|---|
| Founded | 1924 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.1M | 221.9M |
| IPO Year | 2021 | 2015 |
| Metric | EMBC | ACIU |
|---|---|---|
| Price | $3.37 | $2.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $18.50 | $10.00 |
| AVG Volume (30 Days) | ★ 2.4M | 256.1K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 6.88% | N/A |
| EPS Growth | ★ 20.90 | N/A |
| EPS | ★ 0.67 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.17 | $706.75 |
| Revenue Next Year | N/A | $321.13 |
| P/E Ratio | $5.13 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.77 | $2.03 |
| 52 Week High | $15.55 | $4.00 |
| Indicator | EMBC | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 48.77 | 43.52 |
| Support Level | $3.03 | $2.15 |
| Resistance Level | $3.48 | $2.66 |
| Average True Range (ATR) | 0.14 | 0.14 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 66.27 | 34.31 |
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.